Increased serum carcinomic antigen 19-9(CA 19-9) in a dermoid cyst

Journal of Obstetrics and Gynaecology

Volumn 27, Issue 1, 2007, Pages 96-97

  Nanayakkara, S ^a   Ali, S ^b   Gilmour, K ^a,c  

^a TAMESIDE GENERAL HOSPITAL   (United Kingdom)

^b ROYAL OLDHAM HOSPITAL   (United Kingdom)

^c TAMESIDE AND GLOSSOP INTEGRATED CARE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; HYSTERECTOMY; OVARY TERATOMA; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY;

CA-19-9 ANTIGEN; DERMOID CYST; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 33847064703     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.1080/01443610601076259     Document Type: Article

References (8)

1. Atabekoglu C, Bozaci EA, Tezcan S. 2005. Elevated carbohydrate antigen 19-9 in a dermoid cyst. International Journal of Gynaecology and Obstetrics 91:262-263.
2. Canney PA, Wilkinson PM, James RD et al. 1985. CA 19-9 as a marker for ovarian cancer: alone and in comparison with CA125. British Journal of Cancer 52:131-133.
3. Ito K. 1992. Significance of CA 19-9 in mature cystic teratoma. Nippon Sanka Fujinka Gakkai Zasshi 44:524-528.
4. Micke O, Schafer U, Willich N. 1999. Persistent elevation of CA 19-9 levels in a patient with an extended retroperitoneal dermoid. Anticancer Research 19:2717-2720.
5. Mikuni M, Makinoda S, Tanaka T et al. 1990. Evaluation of tumor marker in ovarian dermoid cyst. Nippon Sanka Fujinka Gakkai Zasshi 42:479-484.
6. Nagata H, Takahashi K, Yamane Y et al. 1989. Abnormally high values of CA125 and CA 19-9 in women with benign tumors. Gynecologic and Obstetric Investigation 28:165-168.
7. Novakovic S. 2004. Tumor markers in clinical oncology. International Journal of Radiation Oncology 38:73-83.
8. Scully RE, Young RH, Clement PB. 1998. Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. In: Rosai J, Sobin LH, editors. Atlas of tumor pathology. Washington DC: Armed Forces Institute of Pathology. Series 3. Fascicle 23. Section 14.3.